A generics drugmaker has had its Abbreviated New Drug Application for the radiopharmaceutical 177Lu-PNT2003 accepted by the US Food and Drug Administration.
Massachusetts, USA-based Lantheus Holdings (Nasdaq: LNTH) wants to market the generic version of Lutathera for certain gastroentero-pancreatic neuroendocrine tumors.
The company paid POINT Biopharma (Nasdaq: PNT) over $2 billion for rights to the agent at the end of 2022, together with another candidate, 177Lu-PNT2002.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze